

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: FRICK, et al.

Examiner:

Not Yet Known

Serial No.: 10/735,179

Art Unit:

1615

Filed:

December 12, 2003

Title:

 \boxtimes

Novel Aromatic Fluoroglycoside Derivatives. Medicaments Containing These Compounds,

and The Use Thereof

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

August 25,2005

Brian Pritchett Signature

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

(b)	This	Information Disclosure Statement is filed after the period set forth in 37 C.F.R.
	1.97	(b), but is believed to be filed before the mailing date of a final action under §1.113
	or a	notice of allowance under §1.311, whichever occurs first.
	(1)	The undersigned attorney certifies that each item of information contained in this
		Information Disclosure Statement was cited in a communication from a foreign
		patent office in a counterpart foreign application not more than three months prior
		to the filing of this statement;
	(2)	The undersigned attorney certifies that no item of information contained in this
		Information Disclosure Statement was cited in a communication from a foreign
		patent office in a counterpart foreign application or, to the knowledge of the
		undersigned attorney after making reasonable inquiry, was known to any
		individual designated in §1.56(c) more than three months prior to the filing of this
		statement; or
	(3)	This Information Disclosure Statement is accompanied by a transmittal letter in
		which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is

Respectfully submitted,

Barbara E. Kurys, Reg. No. 34,650

Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2965
Telefax (908) 231-2626

Aventis Docket No. DEAV2002/0086 US NP

authorized.

Please type a plus sign	(+) inside this box -	≯ レ
-------------------------	-----------------------	------------

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

AUG 2 9 2005

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 5

Ce	omplete if Known
Application Number	10/735,179
Filing Date	12-12-2003
First Named Inventor	FRICK
Group Art Unit	1615
Examiner Name	
Attorney Docket Number	DEAV2002/0086 - US - NP

				U.S. PATENT DOCU	JMENTS	
Examiner Initials	Cite No.1	U.S. Patent D	Cocument Kind Code ² (If known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		2002/0132807	'	WANG, et. al.	06-25-2001	
		2002/0137903		ELLSWORTH, et. al.	05-20-2002	
		5,190,923		VINCENT, et al.	03-02-1993	
		6,221,633		ERTL, et. al.	04-24-2001	
		6,221,897		BARINGHAUS, et. al.	04-24-2001	
		6,245,744		BARINGHAUS, et. al.	06-12-2001	
		6,342,512		KIRSCH, et. al.	01-29-2002	
		6,624,185		GLOMBIK, et. al.	09-23-2003	
		6,884,812		GLOMBIKet, al.	04-26-2005	

				FOR	EIGN PATENT DOCUMENT	rs		
Examiner Initials*	Cite No.1	Foreign Patent Document Kind Code ³ Office ³ Number ⁴ (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Fiqures Appear	T ₆	
		EP	0850948		TSUJIHARA, et. al.	07-01-1998		
		EP	0953357	. –	SUZUKI, et. al.	11-03-1999		T
	EP 1213296 A1	_	FUJIKURA, et. al.	06-12-2002				
		JP	2000-80041		KENJI, et. al.	03-21-2000		
		wo	00/40569		HODSON, et, al.	07-13-2000		T
		wo	00/63208		DORWALD, et. al.	10-26-2000		T
		wo	00/64876		JAYYOSI, et. al.	11-02-2000		
		wo	00/64888		JAYYOSI, et. al.	11-02-2000		
		wo	00/66585		HORVATH, et. al.	11-09-2000		T
		wo	00/71549		BROUGH, et. al.	11-30-2000		

Examiner	Date	
Signature	Considered	_

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box 😑	Please	type a	plus	sign	(+)	inside	this box	_
---	--------	--------	------	------	-----	--------	----------	---

Sheet

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control nur

Substitute t	for form 1449A/PTC)		Complete if Known Application Number 10/735,179			
INFO	RMATION	DI	SCLOSURE	Filing Date	12-12-2003		
STAT	EMENT B	YA	APPLICANT	First Named Inventor	FRICK		
				Group Art Unit	1615		
(u	use as many shee	ets as	s necessary)	Examiner Name			
heet	2	of	5	Attorney Docket Number	DEAV2002/0086 - US - NP		

				U.S. PATENT DOCL	JMENTS	
Examiner Initials	Cite No. ¹	U.S. Paten Number	t Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
			-			
					ļ. <u></u>	
					<u> </u>	
					<u> </u>	
			\longrightarrow			

			<u> </u>	FOR	EIGN PATENT DOCUMENT	rs .		
Examiner Initials*	Cite No.1	Office	Foreign Patent Do Number4	cument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
		wo	00/78312		SAHOO, et. al.	12-28-2000		
		wo	01/09111		BRINER, et. al.	02-08-2001		
		wo	01/16147		FUJIKURA, et. al.	03-08-2001		
		wo	01/27128		ELLSWORTH, et. al.	04-19-2001		
		wo	01/68660		ELLSWORTH, et. al.	09-20-2001		
		wo	01/74834	İ	WASHBURN, et. al.	10-11-2001		
		wo	01/74835		WASHBURN, et. al.	10-11-2001		
		wo	01/83451		IKUTA, et. al.	11-08-2001		Γ
		wo	01/85695		LI, et. al.	11-15-2001		
	, and the second	wo	01/91752		BAKSHI, et. al.	12-06-2001		

Examiner	Date	,
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please	type	а	plus	sign	(+)	inside	this box	\rightarrow
--------	------	---	------	------	-----	--------	----------	---------------

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-093/
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO

INFORMATI	ON	DISC	LOSU	RE
STATEMEN	T B	Y API	PLICA	NT

(use as many sheets as necessary)

Sheet 3 of 5

ond to a concension or intermedia	The section of the se						
Complete if Known							
Application Number	10/735,179						
Filing Date	12-12-2003						
First Named Inventor	FRICK						
Group Art Unit	1615						
Examiner Name							
Attorney Docket Number	DEAV2002/0086 - US - NP						

			_	U.S. PATENT DOCL	IMENTS	
Examiner Initials	Cite No.1	U.S. Pater Number	Kind Code ²	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
				· · · · · · · · · · · · · · · · · · ·		
			\longrightarrow	· · · · · · · · · · · · · · · · · · ·		
						
-	_				 	
			- - -	· •	 	
-				- · · · · · · · · · · · · · · · · · · ·	 	
					 	
			_			
			\longrightarrow			
					ļ — — —	
						· · · · · · · · · · · · · · · · · · ·
					<u> </u>	

				FOR	EIGN PATENT DOCUMENT	rs		
Examiner Initials	Cite No.1	Office	Kind Code ⁵ Applicant of Cited Document Cited I		Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	
		wo	02/068439		NISHIMURA, et. al.	09-06-2002		
		wo	02/068440		KFUSHIMI, et. al.	09-06-2002	-	
		wo	02/080935		BUSSOLARI, et. al.	10-17-2002		
		wo	02/080936		BUSSOLARI, et. al.	10-17-2002		
		wo	02/28872		FUJIKURA, et. al.	04-11-2002		
		wo	02/36602		OHSUMI, et. al.	05-10-2002	-	
		wo	02/44192		FUJIKURA, et. al.	06-06-2002		
		wo	95/23780		KVALNES, et. al.	09-08-1995		
		wo	97/26265		NIELSEN, et. al.	07-24-1997		
		wo	97/41097		LOHRAY, et. al.	11-06-1997		

Examiner	Date	
Signature	Considered	

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type	a	plus	sign	(+)	inside	this box	→
-------------	---	------	------	-----	--------	----------	---

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitu	te for form 1449A/PTC)		Complete if Known			
	0011 A T1011	D 14	201.001155	Application Number	10/735,179		
INF	ORMATION	DI	SCLOSURE	Filing Date	12-12-2003		
STA	TEMENT B	YA	PPLICANT	First Named Inventor	FRICK		
				Group Art Unit	1615		
(use as many sheets as necessary)				Examiner Name			
Sheet	4	of	5	Attorney Docket Number	DEAV2002/0086 - US - NP		

	U.S. PATENT DOCUMENTS									
Examiner	u.S. Patent Document		Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines,					
Initials	No.1	Number	Kind Code ² (<i>if known</i>)	of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear				
				••						
_										

				FOF	REIGN PATENT DOCUMEN	rs		
Examiner Initials*	Cite No. ¹	Office	Foreign Patent Document Kind Code ⁵ Number ⁴ (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	I.e
		wo	97/49736		FORSTER, et. al.	12-31-1997		
		wo	98/08871		KNUDSEN, et. al.	03-05-1998		
		wo	99/03861		NIELSON, et. al.	01-28-1999		
		wo	99/15525		BRODIN, et. al.	04-01-1999		oxdapprox
						+		╁
		<u> </u>						
<u> </u>		├						┼—

Examiner	Date	-
Signature	 Considered	

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please	type	a plus	sign	(+)	inside	this	box	→	7
	·) F -		3	٠,				-	

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	ite for form 1449B/F	то		Complete if Known					
				Application Number	10/735,179				
INFO	ORMATIC)N D	ISCLOSURE	Filing Date 12-12-2003					
STA	TEMENT	BY	APPLICANT	First Named Inventor	FRICK				
• • • • • • • • • • • • • • • • • • • •			, <u></u>	Group Art Unit	1615				
	(use as man	y sheet	s as necessary)	Examiner Name					
Sheet	5	of	5	Attorney Docket Number	DEAV2002/0086 - US - NP				


OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		ASAKAWA A., et. al., Cocaine-Amphetamine-Regulated Transcript Influences Energy Metabolism, Anxiety and Gastric Emptying in Mice, Hormone Metabolism Research, (2001), Vol. 33, pp. 554 - 558	
		OKADA, H., et. al., Synthesis and Antitumor Activities of Prodrugs of Benzoylphenylureas, Chem. Pharm. Bull. Vol. 42, Issue 1, 1994, pp. 57-61	
		LEE D. W., et. al., Leptin agonists as a potential approach to the treatment of obesity, Drugs of the Future, (2001), Vol. 26, No. 9, pp. 873 - 881	
		SALVADOR, J., et. al., Perspectives In The Therapeutic Use Of Leptin, Expert Opinion Pharmacotherapy, (2001), Vol. 2, No. 10, pp. 1615 - 1622	
		TYLE, P. et. al., lontophoretic Devices for Drug Delivery, Pharmaceutical Research, (1986), Vol. 3, No. 6, pp. 318 - 326	
		WITHERS, S.G., et. al., 2-Deoxy-2-Fluoroglucosides: A Novel Class of Mechanism-Based Glucosidase Inhibitors, J. Am. Chem. Soc. (1987) Vol. 109 pp. 7530-7531	
		ZUNFIT, H. J. F., et. al., Carob Pulp Preparation for Treatment of Hypercholesterolemia, Advances In Therapy, (2001), Vol. 18, No. 5, pp. 230 - 236	
Examiner		Date	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered

Signature



¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.